Gastric cancer (GC) is currently recognized as one of the most common and fatal tumor worldwide. The identification of novel biomarkers in relation to clinical information as well as extending the knowledge on a multiple crosstalk between various oncogenic pathways implicated in GC carcinogenesis seems pivotal to limit the disease-associated mortality. Therefore, we assessed the expression of HER2, NF-κB, and SATB1 in a total of 104 gastric adenocarcinomas and 30 normal gastric samples and correlated the expression patterns with each other and with some clinicopathological variables. Protein expression was examined by immunohistochemistry (IHC) on tissue microarrays (TMAs), and fluorescence in situ hybridization (FISH) was employed to detect HER2 amplification. In the studied group, HER2 and SATB1 were found to be overexpressed in gastric cancer tissue in comparison to normal gastric mucosa. The expression status of the former protein was seen to differ according to some clinicopathological features, but without statistical significance, whereas the expression of the latter was not importantly associated with any of them. In turn, the NF-κB protein level was significantly related to the presence of lymph node metastasis. HER2 expression was not significantly correlated with that of other proteins, but a positive correlation was found between the expression of SATB1 and NF-κB. Further studies with a larger group of patients combined with in vitro mechanistic experiments are required to fully elucidate the role and relationship of HER2, NF-κB, and SATB1 expression in gastric cancer progression. However, to the best of our knowledge, this study is the first look at a simultaneous evaluation of these three markers in the samples of gastric cancer patients.
Copyright © 2019 Marta Smolińska et al.
Conflict of interest statement
The authors declare that there is no conflict of interest regarding the publication of this article.
Expression of SATB1 and HER2 in Gastric Cancer and Its Clinical SignificanceCL Yuan et al. Eur Rev Med Pharmacol Sci 20 (11), 2256-64. PMID 27338049.High expression of SATB1 gene predicts advanced TNM stage and possible distant metastasis in patients with GC, which was a sign of poor prognosis. The expression of SATB1 …
Correlation of Human Epidermal Growth Factor Receptor 2 Expression With Clinicopathological Characteristics and Prognosis in Gastric CancerC He et al. World J Gastroenterol 19 (14), 2171-8. PMID 23599643.Patients with intestinal type gastric cancer (GC), well-differentiated GC and poorly-differentiated GC without lymph node metastasis, may all represent suitable candidate …
Expression of SATB1 and HER2 in Breast Cancer and the Correlations With Clinicopathologic CharacteristicsX Liu et al. Diagn Pathol 10, 50. PMID 25956130.SATB1 and HER2 performed a synergistic effect in breast cancer. Their expression correlated with poorly differentiated breast cancer and indicated an unfavorable prognosi …
Clinicopathological Factors Associated With HER2 Status in Gastric Cancer: Results From a Prospective Multicenter Observational Cohort Study in a Japanese Population (JFMC44-1101)S Matsusaka et al. Gastric Cancer 19 (3), 839-51. PMID 26265390.HER2 expression in Japanese patients was comparable to that in other populations examined. Intestinal type was an independent factor related to HER2 positivity and low HE …
The Clinicopathological Parameters and Prognostic Significance of HER2 Expression in Gastric Cancer Patients: A Meta-Analysis of LiteratureYY Lei et al. World J Surg Oncol 15 (1), 68. PMID 28327158. - ReviewThis study showed that HER2 overexpression was associated with poor prognosis in gastric cancer patients. HER2 positive rates may be associated with sex, tumor site, TNM …